X-linked Hypophosphatemia is a rare, inherited disorder affecting bone mineralization characterized by abnormal bone development and low levels of phosphate in the blood. The condition is caused by mutations in the PHEX gene which lead to increased levels of fibroblast growth factor 23 (FGF23) that regulates phosphate metabolism and vitamin D activation. Some key signs and symptoms include bone pain, skeletal abnormalities, short stature and fractures. Treatment involves lifelong supplementation with oral phosphate and active vitamin D to normalize blood levels of phosphate and promote bone mineralization.
The X-linked Hypophosphatemia Market is estimated to be valued at US$ 1.5 Bn in 2024 and is expected to exhibit a CAGR of 9.4% over the forecast period 2024-2031.
Key Takeaways
Key players - Key players operating in the X-linked Hypophosphatemia are Ultragenyx Pharmaceutical, Kyowa Kirin, Ascendis Pharma, Pfizer, and Chiesi Farmaceutici. Ultragenyx Pharmaceutical markets burosumab under the brand name Crysvita for treatment of XLH.
Growing demand - Rising prevalence of rare genetic conditions and growing access to specialized treatments is fueling demand for novel treatment options for XLH management. According to public health data, around 1 in 20,000 people are affected by XLH worldwide annually.
Technological advancement - Advancements in gene therapies and development of newer drug delivery technologies is anticipated to revolutionize XLHP treatment landscape in the coming years. Companies are investing heavily in R&D of recombinant protein and gene therapies to provide sustainable symptom relief.
Market Trends
Pipeline strength - Strong product pipeline with over ten candidates in clinical trials including gene therapies is boosting market growth prospects. If approved, these novel therapies can address unmet needs and become standard of care options.
Increasing awareness - Growing patient advocacy initiatives by non-profit groups along with rising medical education regarding genetic conditions is raising awareness about early diagnosis and management of XLH. This is encouraging more patients to seek long-term treatment.
Market Opportunities
Emerging markets - Underpenetrated developing regions of Asia Pacific and Latin America with growing healthcare infrastructure present significant commercialization opportunities for industry players.
Novel formulations - Demand for improved oral and injectable dosage forms to enhance patient adherence and compliance presents lucrative R&D opportunities in the market.
Impact Of COVID-19 On X-Linked Hypophosphatemia Market Growth
The COVID-19 pandemic has significantly impacted the growth of the X-linked Hypophosphatemia Market in various ways. During the pre-COVID times, the market was growing steadily owing to the availability of effective drugs and supportive care. However, during the pandemic, the market experienced slower growth initially due to several factors such as travel restrictions affecting supply chains, reduced demand due to decline in discretionary spending on healthcare and postponement of non-urgent treatments. This led to a short-term decline in revenues for key players.
However, post-COVID trends indicate that the market is recovering gradually and is projected to witness steady growth over the forecast period. With restrictions easing in most parts of the world, healthcare facilities and providers are gearing up to cope with the backlog in treatments. Several manufacturers are focusing on expanding their production capacities and restarting supply chains to meet the rising demand for drugs. Moreover, governments in various countries are prioritizing healthcare to prevent disruption of essential services. Telehealth and teleconsultation have also emerged as favorable alternatives for routine check-ups and medication compliance during such times. Overall, the medium to long term outlook for the market remains positive due to the availability of advanced treatment options and supportive initiatives.
Geographical Concentration In X-Linked Hypophosphatemia Market
In terms of value, North America represents the largest regional market for X-linked hypophosphatemia currently. This is attributed to factors such as high healthcare expenditure, strong reimbursement policies, presence of major market players and adoption of advanced therapies. Within the region, the United States captures the major share due to large patient pool and sophisticated medical infrastructure.
Europe follows North America as the second largest regional market owing to government support for orphan disease research and availability of medications through public healthcare programs across several countries. However, over the forecast period, Asia Pacific is projected to demonstrate the fastest growth rate in the global market due to rising medical tourism, increasing disposable incomes and expansions of coverage under universal healthcare initiatives in various developing nations.
Fastest Growing Region In X-Linked Hypophosphatemia Market
Asia Pacific is currently the fastest growing region in the X-linked Hypophosphatemia Market and is expected to continue exhibiting strong growth prospects till 2031. This rapid expansion can be attributed to multiple factors like rising health awareness, growing per capita incomes, improving access to advanced healthcare services in emerging Asian countries like India, Indonesia, Malaysia, Philippines and Thailand. Moreover, various companies are also focusing on expanding their footprint in the region through collaborations with local players and strategic initiatives like setting up manufacturing units. The rising middle class patient pool, favorable government policies supporting medical research and presence of low-cost generics are further expected to drive the Asia Pacific market during the forecast period.
Get more insights on this topic: https://www.trendingwebwire.com/x-linked-hypophosphatemia-treatment-market-is-estimated-to-witness-high-growth-owing-to-advancements-in-gene-therapy/
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)
What Are The Key Data Covered In This X-linked Hypophosphatemia Market Report?
:- Market CAGR throughout the predicted period
:- Comprehensive information on the aspects that will drive the X-linked Hypophosphatemia Market's growth between 2024 and 2031.
:- Accurate calculation of the size of the X-linked Hypophosphatemia Market and its contribution to the market, with emphasis on the parent market
:- Realistic forecasts of future trends and changes in consumer behaviour
:- X-linked Hypophosphatemia Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa
:- A complete examination of the market's competitive landscape, as well as extensive information on vendors
:- Detailed examination of the factors that will impede the expansion of X-linked Hypophosphatemia Market vendors
FAQ’s
Q.1 What are the main factors influencing the X-linked Hypophosphatemia Market?
Q.2 Which companies are the major sources in this industry?
Q.3 What are the market’s opportunities, risks, and general structure?
Q.4 Which of the top X-linked Hypophosphatemia Market companies compare in terms of sales, revenue, and prices?
Q.5 Which businesses serve as the X-linked Hypophosphatemia Market’s distributors, traders, and dealers?
Q.6 How are market types and applications and deals, revenue, and value explored?
Q.7 What does a business area’s assessment of agreements, income, and value implicate?
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
Comments
0 comment